Ontology highlight
ABSTRACT: Objective
Adjuvantation of an H5N1 split-virion influenza vaccine with AS03(A) substantially reduces the antigen dose required to produce a putatively protective humoral response and promotes cross-clade neutralizing responses. We determined the effect of adjuvantation on antibody persistence and B- and T-cell-mediated immune responses.Methods
Two vaccinations with a split-virion A/Vietnam/1194/2004 (H5N1, clade 1) vaccine containing 3.75-30 ?g hemagglutinin and formulated with or without adjuvant were administered to groups of 50 volunteers aged 18-60 years.Results
Adjuvantation of the vaccine led to better persistence of neutralizing and hemagglutination-inhibiting antibodies and higher frequencies of antigen-specific memory B cells. Cross-reactive and polyfunctional H5N1-specific CD4 T cells were detected at baseline and were amplified by vaccination. Expansion of CD4 T cells was enhanced by adjuvantation.Conclusion
Formulation of the H5N1 vaccine with AS03(A) enhances antibody persistence and induces stronger T- and B-cell responses. The cross-clade T-cell immunity indicates that the adjuvanted vaccine primes individuals to respond to either infection and/or subsequent vaccination with strains drifted from the primary vaccine strain.
SUBMITTER: Moris P
PROVIDER: S-EPMC3132412 | biostudies-literature | 2011 Jun
REPOSITORIES: biostudies-literature
Moris Philippe P van der Most Robbert R Leroux-Roels Isabel I Clement Frédéric F Dramé Mamadou M Hanon Emmanuel E Leroux-Roels Geert G GG Van Mechelen Marcelle M
Journal of clinical immunology 20101221 3
<h4>Objective</h4>Adjuvantation of an H5N1 split-virion influenza vaccine with AS03(A) substantially reduces the antigen dose required to produce a putatively protective humoral response and promotes cross-clade neutralizing responses. We determined the effect of adjuvantation on antibody persistence and B- and T-cell-mediated immune responses.<h4>Methods</h4>Two vaccinations with a split-virion A/Vietnam/1194/2004 (H5N1, clade 1) vaccine containing 3.75-30 μg hemagglutinin and formulated with o ...[more]